Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy-Reference-Cited by-同舟云学术

Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy

Published:2021-01-01 Issue:1 Volume:38 Page:120-129
ISSN:0265-6736
Container-title:International Journal of Hyperthermia
language:en
Short-container-title:International Journal of Hyperthermia

Author:

Chen Shuanggang¹²,Wu Ying¹²,Qi Han¹²,Shen Lujun¹²,Ma Weimei²³,Cao Fei¹²,Diao Yuhong¹²,Wang Ting¹²,Ou Shunling¹²,Fan Weijun¹²

Affiliation:

1. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, People’s Republic of China

3. Department of Radiology, The Eighth Affiliated Hospotal, Sun Yat-sen University, Shenzhen, People’s Republic of China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Cancer Research,Physiology (medical),Physiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/02656736.2021.1876930

Reference31 articles.

1. Cancer statistics, 2012

2. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation

3. AASLD guidelines for the treatment of hepatocellular carcinoma

4. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

5. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy;International Immunopharmacology;2023-06